COMP <GO>
MIRM vs LLY // NET PROFIT MARGIN
Mirum Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MIRM 2
— LLY 12
▲ NET PROFIT MARGIN LEADER: LLY
LAST: $85.00 (-1.61%) • MKT CAP: $5.61B
net-margins
-4.50%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
net-margins
31.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIRM | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 32.36% | -36.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.98% | 2.30% | -1.32 | LLY | /fcf-yield <GO> |
| Operating Margin | -4.20% | 40.21% | -44.41 | LLY | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -4.50% | 31.90% | -36.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 54.70% | 45.51% | +9.19 | MIRM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.29 | 9.29 | -3.00 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 77.9 | -29.19 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.51 | +0.48 | MIRM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 26.3x | +5.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.61B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIRM REV | LLY REV | MIRM GROSS % | LLY GROSS % | MIRM FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $521.3M | $65.18B | 44.0% | 83.0% | $54.9M | $16.81B |
| FY 2024 | $336.9M | $45.04B | 44.0% | 81.3% | $9.3M | $8.82B |
| FY 2023 | $186.4M | $34.12B | 44.0% | 79.3% | -$79.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
LLY // BETA 0.51